Compare NDAQ & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NDAQ | BDX |
|---|---|---|
| Founded | 1971 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.3B | 55.7B |
| IPO Year | 2002 | 1962 |
| Metric | NDAQ | BDX |
|---|---|---|
| Price | $99.15 | $196.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 9 |
| Target Price | $102.14 | ★ $213.13 |
| AVG Volume (30 Days) | ★ 3.9M | 1.9M |
| Earning Date | 01-28-2026 | 02-04-2026 |
| Dividend Yield | 1.09% | ★ 2.14% |
| EPS Growth | ★ 66.50 | N/A |
| EPS | 2.80 | ★ 5.82 |
| Revenue | $8,168,000,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | N/A | $4.02 |
| Revenue Next Year | $7.88 | $3.37 |
| P/E Ratio | $35.49 | ★ $33.73 |
| Revenue Growth | ★ 16.40 | 8.24 |
| 52 Week Low | $64.84 | $162.29 |
| 52 Week High | $99.42 | $251.99 |
| Indicator | NDAQ | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 79.98 | 55.10 |
| Support Level | $92.18 | $194.82 |
| Resistance Level | $94.38 | $198.10 |
| Average True Range (ATR) | 1.56 | 3.61 |
| MACD | 0.66 | -0.32 |
| Stochastic Oscillator | 100.00 | 54.88 |
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its trading business (about 22.5% of sales), the company sells market and financial data to investors, offers Nasdaq-branded indexes, and lists companies through its capital access segment (42.5%). Nasdaq's newest segment, financial technology, was primarily constructed through the acquisitions of Verafin and Adenza and has expanded the company into capital management, financial crime, and regulatory compliance software (35%) as it seeks to become a diversified technology company.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.